Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Risk of Infections Associated with the Use of Monoclonal Antibodies in Multiple Myeloma (MM)

Version 1 : Received: 22 May 2024 / Approved: 22 May 2024 / Online: 23 May 2024 (08:17:48 CEST)

How to cite: Mele, G. Risk of Infections Associated with the Use of Monoclonal Antibodies in Multiple Myeloma (MM). Preprints 2024, 2024051458. https://doi.org/10.20944/preprints202405.1458.v1 Mele, G. Risk of Infections Associated with the Use of Monoclonal Antibodies in Multiple Myeloma (MM). Preprints 2024, 2024051458. https://doi.org/10.20944/preprints202405.1458.v1

Abstract

Patients with Multiple Myeloma have an increased susceptibility to severe infections due to several various factors, especially the high tumor burden. The use of the anti-CD38 monoclonal antibodies-based therapies has changed the frequency and epidemiology of infections. We report herein the safety profile of the pivotal clinical trials conducted with anti-CD38 mAbs (daratumumab and isatuximab) and anti-SLAMF7 mAbs (elotuzumab) that led to the approval of regimens employed today in NDMM and RRMM patients.

Keywords

infectious diseases, Multiple Myeloma, monoclonal antibody based-strategies

Subject

Medicine and Pharmacology, Hematology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.